Dexamethasone Solution for the Treatment of Oral Lichen Planus

Status Completed

Clinical Trial Summary

The objective of this single center, 4-week, open label randomized, phase II study is to evaluate and characterize the tolerability and clinical effectiveness of dexamethasone 0.5mg/5ml solution in a mucoadhesive vehicle (Mucolox™) for the treatment of oral lichen planus.

Clinical Trial Description

Potentially eligible subjects will be screened by one of the investigators by asking patients to rate their worst oral pain or pain score (0-10) over the previous week (see Appendix). Those answering with at least a score of "7" (1/10) and that meet all other eligibility requirements (see Section 3) will be eligible for enrollment. All patients will sign informed consent for study participation. Each study visit is anticipated to take approximately 45 minutes. Treatment will be administered on an outpatient basis. Study medication will be prescribed by authorized study staff physicians at no expense for the patient. Subjects will be evaluated clinically at baseline before starting treatment and at the end of the four-week period, for a total of two visits. Comprehensive subjective and objective data will be collected and intraoral photographs will be obtained. Oral mucosal disease will be evaluated using both patient reported (questions/visual analog scales) and clinician assessed measures. Subjects will be prescribed compound dexamethasone 0.5mg/5ml solution in Mucolox™ (ARM A) or dexamethasone 0.5mg/5ml solution only (ARM B). All subjects will also receive a prescription for fluconazole 200 mg tablets once-a-week as prophylactic antifungal therapy. Any subjects that are already taking an antifungal oral medication at the time of the study enrollment will continue their prescribed medication and will not need to take the additional weekly fluconazole dose. Subjects will return for evaluation after four weeks at which time the study end-points will be assessed. If there is worsening of oral lichen planus that requires initiation of new immunomodulatory medications (systemic or topical), patients will remain on treatment, but will be regarded as unevaluable for the primary endpoint. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02850601
Study type	Interventional
Source	Brigham and Women's Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	February 7, 2017
Completion date	December 20, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06021405` - Koebner's Phenomenon in Psoriasis and Lichen Planus	N/A
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Completed	`NCT05787925` - Adjunctive Oral Systemic Vitamin E Therapy on Salivary Nitric Oxide Level in Patients With Erosive Oral Lichen Planus	N/A
Completed	`NCT03630198` - Pain Outcomes Following Intralesional Corticosteroid Injections	Phase 4
Completed	`NCT04952961` - Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study	N/A
Recruiting	`NCT04697563` - Laser Therapy in Women With Lichenoid Disorders	N/A
Recruiting	`NCT06451744` - Cellular and Molecular Biomarkers in Patients With Lichen Planus	N/A
Completed	`NCT03265093` - Use of Injectable Platelet Rich Fibrin in Lichen Planus	N/A
Completed	`NCT03858634` - A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases	Phase 2
Completed	`NCT02761122` - Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen)	N/A
Active, not recruiting	`NCT00691106` - A Multi-center Study to Evaluate the Safety of Etanercept in the Treatment of Lichen Planus	Phase 2
Terminated	`NCT05761158` - Study of the Characteristics of Pruritus in Patients With Frontal Fibrosing Alopecia or Lichen Planus Pilaris
Recruiting	`NCT02261662` - Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection	N/A
Not yet recruiting	`NCT04892381` - Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
Completed	`NCT05396261` - a Flexible Wound Dressing for the Management of Genital Skin Conditions	N/A
Recruiting	`NCT02532166` - Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus	N/A
Recruiting	`NCT06327620` - Treatment Of Oral Lichen Planus	N/A
Completed	`NCT03796806` - Methods Validation Assessment for Study of Inflammatory Skin Disease
Not yet recruiting	`NCT01041625` - Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus	Phase 2
Completed	`NCT00824889` - Exploratory Study of Natural Killer Cells in Human Skin	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.